Literature DB >> 21962316

Opioid use, misuse, and abuse in patients labeled as fibromyalgia.

Mary-Ann Fitzcharles1, Peter A Ste-Marie, Ann Gamsa, Mark A Ware, Yoram Shir.   

Abstract

BACKGROUND: As pain is the cardinal symptom of fibromyalgia, it is logical that treatments directed toward pain relief will be commonly used. Analgesic drug therapy remains the traditional treatment intervention for most chronic pain conditions, with a progressive increased use of opioids in the past 20 years. Concerns about efficacy, risk-benefit ratio, and possible long-term effects of chronic opioid therapy have been raised. There is limited information about opioid treatment in fibromyalgia, with all current guidelines discouraging opioid use.
METHODS: A chart review of all patients referred to a tertiary care pain center clinic with a referring diagnosis of fibromyalgia was conducted to evaluate use of opioid medications.
RESULTS: We have recorded opioid use by 32% of 457 patients referred to a multidisciplinary fibromyalgia clinic, with over two thirds using strong opioids. Opioid use was more commonly associated with lower education, unemployment, disability payments, current unstable psychiatric disorder, a history of substance abuse, and previous suicide attempts.
CONCLUSION: We have observed negative health and psychosocial status in patients using opioids and labeled as fibromyalgia. Prolonged use of opioids in fibromyalgia requires evaluation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962316     DOI: 10.1016/j.amjmed.2011.05.031

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  28 in total

Review 1.  The risk of suicide mortality in chronic pain patients.

Authors:  Afton L Hassett; Jordan K Aquino; Mark A Ilgen
Journal:  Curr Pain Headache Rep       Date:  2014

Review 2.  Management of pain with comorbid substance abuse.

Authors:  Daniel Krashin; Natalia Murinova; Jane Ballantyne
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

Review 3.  Fibromyalgia: evolving concepts over the past 2 decades.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; John X Pereira
Journal:  CMAJ       Date:  2013-05-06       Impact factor: 8.262

4.  The use of prescription opioid medication by patients with borderline personality disorder and axis II comparison subjects: a 10-year follow-up study.

Authors:  Frances R Frankenburg; Garrett M Fitzmaurice; Mary C Zanarini
Journal:  J Clin Psychiatry       Date:  2014-04       Impact factor: 4.384

5.  Disrupted brain circuitry for pain-related reward/punishment in fibromyalgia.

Authors:  Marco L Loggia; Chantal Berna; Jieun Kim; Christine M Cahalan; Randy L Gollub; Ajay D Wasan; Richard E Harris; Robert R Edwards; Vitaly Napadow
Journal:  Arthritis Rheumatol       Date:  2014-01       Impact factor: 10.995

6.  Patient-Reported Outcomes: Understanding Surgical Efficacy and Quality from the Patient's Perspective.

Authors:  Jessica I Billig; Erika D Sears; Breanna N Travis; Jennifer F Waljee
Journal:  Ann Surg Oncol       Date:  2019-09-05       Impact factor: 5.344

Review 7.  Fibromyalgia: Treating Pain in the Juvenile Patient.

Authors:  Sabrina Gmuca; David D Sherry
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

8.  Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients.

Authors:  Lucy Chen; Trang Vo; Lindsey Seefeld; Charlene Malarick; Mary Houghton; Shihab Ahmed; Yi Zhang; Abigail Cohen; Cynthia Retamozo; Kristen St Hilaire; Vivian Zhang; Jianren Mao
Journal:  J Pain       Date:  2013-02-26       Impact factor: 5.820

Review 9.  What are we treating with chronic opioid therapy?

Authors:  Daniel Krashin; Mark Sullivan; Jane Ballantyne
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

10.  Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin.

Authors:  Seoyoung C Kim; Joan E Landon; Daniel H Solomon
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.